Medesis Pharma wishes to accelerate the development of its

0

Medesis Pharma wishes to accelerate the development of his anti-nuclear products and provides a point on its strategy

Montpellier (France), April, 52022 – 8:45am – Medesis Pharma (ISIN: FR0010844464, Mnemo: ALMDP), a pharmaceutical biotechnology company developing drug candidates with its proprietary oral active delivery technology, Aonys®, publishes an information note on the three future drugs being developed for the protection of large populations contaminated after a civil or military nuclear accident.

Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. All three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants.

Medesis Pharma’s three drug candidates were developed in collaboration with the Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated with radionuclides, and with the Institute for Biomedical Research armies (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent filed or in the process of being filed in most nuclear countries in the world.

Therapeutic activity has been demonstrated, and a complementary program is needed with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into the emergency stocks of the State.

Applications for funding for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency.

NU01: NanoCaDTPA: Plutonium decorporation
For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (Nuclear Power Plant workers), but impossible to implement when several hundred thousand people are contaminated.
The NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with a simple administration in the mouth, from a bottle stored at room temperature.

NU02: NanoPB (prussian blue): VSandSie decorporation
Prussian blue has been used for many years for the extraction of cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by stubborn constipation resulting in irradiation of the small pelvis. However, cesium binds preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents.
The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and can be given to any age, including infants and children.

NP02: NanoManganese
The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the radiation-triggered inflammatory cytokine storm that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered orally and stored in vials at room temperature.
This product is currently in a phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm.

General information about a nuclear explosion

  • During an explosion, a nuclear weapon first generates a ball of fire whose size varies with the power. A 1 kiloton bomb would thus generate a ball 60 meters in diameter causing damage up to 2 kilometers around the point of impact. A 1,000 kiloton bomb would generate a fireball over a kilometer long whose impact could have a radius of up to 20 kilometres.
  • Blast effect: the explosion causes a shock wave with a displacement of an air mass capable of destroying all surrounding objects. The vacuum created by the moving air then drives strong winds, similar to a cyclone or tornado;
  • Heat: the light radiation and its heat, which represent more than a third of the energy of the bomb, cause fires and burns on people;
  • Radiation: the bomb generates direct radiation when it explodes;
  • Radioactive pollution that can be carried by the winds over great distances by radionuclides that are absorbed by the respiratory and digestive tracts, settle in the tissues, including the lungs, liver, bones and heart, and will never be eliminated again and will cause cancer 10 to 15 years later.

Product development plan
For each of the two decorporation products of Plutonium and Cesium:
• Development of pharmaceutical CMC with preparation for industrial production,
• Tolerance study on 50 healthy volunteers treated for one month.
For the radiation protection product already in clinical development:
• Industrial development,
• Tolerance study on 50 healthy volunteers for one month.

Deadlines for product registration and industrial manufacturing:
• 18 months for the two decorporation products
• 12 months for the radiation protection product
In practice, these deadlines can be shortened or extended depending on whether the Medicines Agency and the public authorities deem it urgent or not.

About Medesis Pharma
To advance in the treatment of serious diseases for which there is no effective treatment, Medesis Pharma has designed drug candidates based on its proprietary Aonys® technology for administering active ingredients in the form of nano-droplets by oral route, which makes the delivery active ingredients in all cells, with passage of the Blood-Brain Barrier
This innovative approach is applied to future drugs to treat major diseases for which there are no effective treatments: Alzheimer’s disease, Huntington’s disease, certain resistant cancers and severe respiratory inflammation such as those linked to COVID-19. Medesis Pharma also develops treatments dedicated to populations irradiated after a civil or military nuclear accident.
A French biopharmaceutical company deployed near Montpellier, Medesis Pharma is the source of 15 scientific publications, holds 11 international patents, the fruit of 17 years of research and is now more particularly dedicated to 4 projects which are entering clinical Phase II in the field of neurodegenerative diseases and the treatment of Covid-19. Recognized worldwide, Medesis Pharma is also working on new applications of its technology in partnership with public research laboratories (CNRS, CEA, IRBA), major university hospital centers in France, Canada and the United States as well as players private, like Transgene.
Medesis Pharma shares are listed on Euronext Growth Paris. FR0010844464 – ALMDP

MEDESIS PHARMA
Tessa Olivato
Tel: +33 4 67 03 03 96
[email protected]

CALYPTUS
Mary Calleux
Tel: +33 1 53 65 68 66
[email protected]

For more information: www.medesispharma.com

  • Decorporation-nucleaire_FR_20220405

Share.

Comments are closed.